U.S. IT Stock News

Over the last 7 days, the United States market has dropped 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth prospects.

Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth.

Over the last 7 days, the U.S. market has dropped 2.5%, though it has seen a significant rise of 23% over the past year, with earnings forecasted to grow annually by 17%. In light of these conditions, investors might find value in exploring stocks that offer affordability and growth potential, particularly those with strong financials. Although the term "penny stocks" may seem outdated, these smaller or newer companies continue to present intriguing opportunities for those seeking...

Over the last 7 days, the United States market has dropped by 2.5%, yet it has seen a significant rise of 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this dynamic environment, dividend stocks that offer consistent payouts and potential for capital appreciation can be a valuable addition to an investment portfolio.

Nektar Therapeutics recently launched preparations for its Phase 3 ZENITH-AD program for rezpegaldesleukin in atopic dermatitis, alongside presenting at the Jefferies Global Healthcare Conference 2026 and issuing inducement stock options to new hires under its 2025 Inducement Plan. The move to start a five-trial Phase 3 program for rezpegaldesleukin, in an atopic dermatitis market facing entrenched competitors and biosimilars, could be a pivotal test of Nektar’s immunology-focused business...

Recent performance snapshot Saul Centers (BFS) has drawn fresh attention after a period of steady share price moves, with the stock up around 0.1% today and positive returns over the week, month, past 3 months and year to date. See our latest analysis for Saul Centers. With the share price at $36.54, Saul Centers has logged a 7-day share price return of 5.61% and a year to date share price return of 15.78%. The 1-year total shareholder return of 12.57% suggests recent momentum is building on...

Ellington Financial recently reported its fourth consecutive quarterly earnings beat, driven by strong transaction volumes and organic growth in its credit portfolio, while continuing to offer a monthly dividend yield above 11%, a development that occurred prior to today. This combination of consistent earnings outperformance and a high recurring income stream stands out in a mortgage and credit sector facing margin pressure and weaker loan demand. We’ll now examine how Ellington Financial’s...

Chagee Holdings stock reaction and recent performance Chagee Holdings (CHA) stock has traded quietly in recent sessions, giving investors space to reassess the teahouse operator after a mixed period that includes a decline over the past year and gains in the past 3 months. See our latest analysis for Chagee Holdings. At the latest share price of $11.54, Chagee Holdings shows a 7.75% 90-day share price return but a much weaker 1-year total shareholder return, which is down 62.53%. This...

Recent stock move and what it might mean Newsmax (NMAX) has caught investor attention after a sharp move in its share price, with the stock down 4.8% in the latest session but up 43.7% over the past month. That swing comes against a mixed return picture, including a 4.7% gain over the past week, a 29.6% rise over the past 3 months, and a 38.3% decline over the past year. This has prompted fresh questions about how the company’s fundamentals stack up against recent trading. See our latest...

Bausch + Lomb (BLCO) is back in focus after announcing the U.S. launch of Blink Triple Care Preservative Free eye drops, a preservative free, multi dose dry eye product built on a clinically tested formula. See our latest analysis for Bausch + Lomb. The product launch lands at a time when Bausch + Lomb’s 1 year total shareholder return of 29.05% contrasts with a share price that is down 9.70% over 90 days and 6.76% year to date, suggesting recent momentum has cooled after a stronger year. If...

Dianthus Therapeutics recently advanced its pipeline as the FDA eased safety requirements for claseprubart trials and granted the program orphan drug designation, while the company also prioritized its dual-mechanism autoimmune candidate DNTH212 with key clinical milestones scheduled through 2028. These regulatory and clinical developments, coupled with upcoming conference commentary, highlight how streamlined trial execution and targeted rare-disease positioning could reshape perceptions of...

Global inflation worries, rising bond yields and energy price swings are keeping markets on edge, which is why many investors are focusing on companies with strong balance sheets and efficient use of shareholder capital. The Solid Balance Sheet and Fundamentals screener highlights stocks with high return on equity, resilient past performance and prudent financial structures, qualities that can help support earnings quality when conditions are choppy. In this article, you will see 3 stocks...

Clinical data and regulatory milestones in focus Zenas BioPharma (ZBIO) stock is drawing attention after the company reported detailed Phase 3 INDIGO data for obexelimab in IgG4-Related Disease and advanced a Biologics License Application with the FDA. See our latest analysis for Zenas BioPharma. Despite the positive INDIGO data and recent Biologics License Application filing, Zenas BioPharma's share price has come under pressure, with the stock down 11.05% over 30 days and 49.36% year to...

Teladoc Health (TDOC) is back in focus after expanding its virtual urgent care, dermatology, and nutrition services onto Walmart’s Better Care Services platform, giving the telehealth provider access to a broader retail customer base. See our latest analysis for Teladoc Health. At a share price of US$7.05, Teladoc Health has seen recent momentum cool, with a 7 day share price return down 10.87% and a 1 year total shareholder return down 4.73%. However, the 90 day share price return, up...

White Mountains Insurance Group (WTM) is back in focus after its 2026 Annual Investor Presentation, which outlined 2025 results, growth in book value per share, record capital deployment, and several portfolio transactions. See our latest analysis for White Mountains Insurance Group. The 1-year total shareholder return of 15.61% contrasts with a softer 90-day share price return, which fell 7.12%. This suggests momentum has cooled even as investors who stayed invested longer have seen stronger...

Investors who take an interest in Infinity Natural Resources, Inc. ( NYSE:INR ) should definitely note that the...

We'd be surprised if Consensus Cloud Solutions, Inc. ( NASDAQ:CCSI ) shareholders haven't noticed that the Independent...

Some MongoDB, Inc. ( NASDAQ:MDB ) shareholders may be a little concerned to see that the Independent Director, Roelof...

Anyone interested in VTEX ( NYSE:VTEX ) should probably be aware that the Co-founder, Mariano Gomide de Faria, recently...

Over the last 7 days, the United States market has experienced a 2.5% drop, yet it remains up by 23% over the past year with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying stocks that are undervalued and exhibit insider buying can be an effective strategy for investors seeking opportunities in small-cap companies across various regions.

Over the last 7 days, the United States market has experienced a 2.5% decline, though it has seen a significant rise of 23% over the past year, with earnings projected to grow by 17% annually. In this context, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets in an evolving market landscape.

Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 23% over the past year, with earnings projected to grow by 17% annually in the coming years. In this fluctuating environment, identifying growth companies with high insider ownership can be particularly appealing as these firms often demonstrate strong potential and a vested interest from those who know them best.

Over the last 7 days, the United States market has dropped 2.5%, but it remains up 23% over the past year with earnings forecasted to grow by 17% annually. For investors looking beyond well-known stocks, penny stocks—often representing smaller or newer companies—can present intriguing opportunities despite their somewhat outdated label. By focusing on those with strong financial health and potential for growth, investors might uncover valuable options in this niche area of the market.

Some Dave Inc. ( NASDAQ:DAVE ) shareholders may be a little concerned to see that the Co-Founder, Jason Wilk, recently...